<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Genetics of Alzheimer disease</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Genetics of Alzheimer disease</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Genetics of Alzheimer disease</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rick Sherva, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Neil W Kowall, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Steven T DeKosky, MD, FAAN, FACP, FANA</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Benjamin A Raby, MD, MPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Janet L Wilterdink, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 19, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H6562986"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Alzheimer disease (AD) is the most common form of dementia, with an estimated lifetime risk of nearly 1 in 5 for women and 1 in 10 for men. AD is highly heritable, even in so-called sporadic cases. The genetic basis for AD is best understood in the early-onset form, which accounts for less than 1 percent of cases and typically follows an autosomal dominant inheritance pattern related to mutations in genes that alter amyloid-beta (Aβ) protein production, aggregation, or clearance. The genetic basis of late-onset AD (LOAD) is more complex, with susceptibility likely conferred by a variety of more common but less penetrant genetic factors, such as apolipoprotein E (<em>APOE</em>) alleles, interacting with environmental and epigenetic influences.</p><p>This topic will review the genetic basis of AD in both early-onset and late-onset forms. Other risk factors for dementia and the clinical manifestations and diagnosis of AD are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5079.html" rel="external">"Risk factors for cognitive decline and dementia"</a> and  <a class="medical medical_review" href="/z/d/html/5071.html" rel="external">"Clinical features and diagnosis of Alzheimer disease"</a>.)</p><p class="headingAnchor" id="H1025787"><span class="h1">APPROACHES TO GENE DISCOVERY</span><span class="headingEndMark"> — </span>The genetic contribution to AD risk remains poorly understood despite major advances in the 1990s in the identification of three genes that cause early-onset familial AD and one genetic risk factor for late-onset AD (LOAD). There have been three main strategies employed to identify genetic factors that predispose to the development of AD: linkage analysis, candidate gene studies, and genome-wide association studies (GWAS). General principles of genetic variation and genetic association studies are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2902.html" rel="external">"Genetic association and GWAS studies: Principles and applications"</a> and  <a class="medical medical_review" href="/z/d/html/2900.html" rel="external">"Basic genetics concepts: DNA regulation and gene expression", section on 'Genetic variation'</a>.)</p><p class="headingAnchor" id="H1027823"><span class="h2">Linkage analysis</span><span class="headingEndMark"> — </span>The first progress in understanding the genetic basis of AD resulted from studies of families displaying autosomal dominant inheritance of the disorder. These studies used linkage-based methodology, in which a relatively small number (on the order of several hundred) of nonfunctional genetic markers spaced throughout the genome are genotyped in order to determine whether a given section of chromosome was transmitted from parents to their offspring. By comparing this information with disease status, the genes responsible can be mapped to relatively large chromosomal regions. Early AD studies used linkage analysis to identify culprit regions on chromosomes 1, 14, and 21, eventually leading to discovery of the three known causative AD genes [<a href="#rid1">1-4</a>]. (See <a class="local">'Early-onset Alzheimer disease'</a> below.)</p><p>Whereas linkage analysis has been very successful in identifying monogenic traits in early-onset familial AD, it has had much more limited success in LOAD, which is more likely to be a complex trait. (See <a class="local">'Challenges'</a> below.)</p><p class="headingAnchor" id="H1025837"><span class="h2">Candidate gene studies</span><span class="headingEndMark"> — </span>Candidate gene studies can include family members or unrelated individuals and require some degree of foreknowledge about the genes and pathways involved in AD. In this approach, one or a small number of known genetic variants, called single nucleotide polymorphisms (SNPs), are genotyped and compared in cases and controls. (See  <a class="medical medical_review" href="/z/d/html/2902.html" rel="external">"Genetic association and GWAS studies: Principles and applications"</a>.) </p><p>Drawing on clues about AD pathogenesis emerging from cell biology and neurochemistry, numerous candidate gene association studies have been conducted in AD. Studies typically focus on loci with potential effects on amyloid-beta (Aβ) production, aggregation, or clearance (ie, a functional hypothesis) or on loci suspected to be important based on prior linkage studies (ie, a positional hypothesis).</p><p>The primary success of the candidate gene approach in LOAD has been the identification of apolipoprotein E (<em>APOE</em>) risk alleles (whose location was identified originally through linkage studies). Subsequently, nearly 700 other candidate genes have been investigated based on functional hypotheses, with mostly inconsistent results. (See <a class="local">'Apolipoprotein E'</a> below and <a class="local">'Other candidate genes'</a> below.)</p><p>As exome and whole-genome sequencing becomes more feasible and cost efficient, the candidate gene approach may yield further insights into the heritability of LOAD.</p><p class="headingAnchor" id="H1025931"><span class="h2">Genome-wide association studies</span><span class="headingEndMark"> — </span>In the first decade of the 21<sup>st</sup> century, microarray technology revolutionized genetics research, making it possible to test hundreds of thousands of candidate genes simultaneously. Such GWAS allow for large-scale, largely hypothesis-free inquiries aimed at identifying novel genetic risk factors for AD. </p><p>In AD, multiple GWAS have been performed to date, largely confirming the importance of <em>APOE </em>and implicating a growing number of other potential loci (see <a class="local">'Other candidate genes'</a> below). To date, information from over 1375 candidate gene and genome-wide association studies, implicating nearly 700 candidate genes, has been curated by the Alzheimer Disease Forum in the <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.alzgene.org%2F&amp;token=0SM8TegfFRL7gaY%2Byqo9TCS0qmw%2BClEHXl5heFr3gcE%3D&amp;TOPIC_ID=16195" target="_blank">AlzGene database</a> [<a href="#rid5">5</a>].</p><p class="headingAnchor" id="H6562978"><span class="h1">EARLY-ONSET ALZHEIMER DISEASE</span><span class="headingEndMark"> — </span>The first progress in understanding the genetic basis of AD resulted from studies of families displaying autosomal dominant inheritance of the disorder. Families with autosomal dominant AD are those with at least three affected individuals in two or more generations, with two of the individuals being first-degree relatives of the third. In these families, affected individuals typically develop symptoms of AD between the ages of 30 and 60 years. Most, but not all, families with early-onset AD show an autosomal dominant pattern of inheritance. The pattern may be masked in small families or those with premature deaths (ie, prior to the anticipated age of clinical symptom onset) from unrelated causes.</p><p>Early studies in families with autosomal dominant AD used linkage-based methodology to isolate relatively large culprit regions on chromosomes 1 [<a href="#rid1">1</a>], 14 [<a href="#rid2">2,3</a>], and 21 [<a href="#rid4">4</a>]. This facilitated the eventual identification of causative mutations in the three genes: amyloid precursor protein (<em>APP</em>) [<a href="#rid6">6</a>], presenilin 1 (<em>PSEN1</em>) [<a href="#rid7">7</a>], and presenilin 2 (<em>PSEN2</em>) [<a href="#rid8">8,9</a>]. Although these mutations collectively account for less than 1 percent of all AD cases and 60 to 70 percent of early-onset AD [<a href="#rid10">10-12</a>], their discovery substantially increased the understanding of basic AD pathophysiology.</p><p class="headingAnchor" id="H2663392"><span class="h2">Amyloid precursor protein</span><span class="headingEndMark"> — </span>The <em>APP</em> gene is located on chromosome 21q and encodes the protein product, APP [<a href="#rid13">13</a>]. More than 30 mutations in this gene have been described in association with AD, accounting for 10 to 15 percent of early-onset familial AD [<a href="#rid11">11,12</a>]. Mutations are fully penetrant, and age of onset is closely correlated with parental age of onset and mutation type [<a href="#rid14">14</a>]. The median age of onset across all mutation types is approximately 49 years  (<a class="graphic graphic_figure graphicRef97086" href="/z/d/graphic/97086.html" rel="external">figure 1</a>). </p><p>The function of APP in neurons is not well understood, but it is believed to be important in synaptic transmission [<a href="#rid15">15</a>]. APP is cleaved proteolytically by three enzymes, known as α-, β-, and γ-secretase. In the amyloidogenic pathway, β-secretase and later γ-secretase cleave APP into two peptides of varying lengths. The longer of the two fragments, amyloid-beta 42 (Aβ42), is more hydrophobic and prone to fibril formation.</p><p>Nearly all pathogenic <em>APP</em> mutations identified so far cluster around the three major processing sites that are relevant to the generation of amyloidogenic Aß, increasing production of Aβ, or altering the ratio of Aβ42 to Aβ40 [<a href="#rid16">16-19</a>]. Most are dominant missense mutations, although rare families with <em>APP</em> locus duplication or recessive inheritance patterns have been reported [<a href="#rid20">20-24</a>].</p><p class="headingAnchor" id="H2663399"><span class="h2">Presenilin 1</span><span class="headingEndMark"> — </span>The <em>PSEN1</em> gene is located on chromosome 14q and encodes the protein product, PSEN1. More than 150 <em>PSEN1 </em>mutations have been described in association with AD, accounting for up to 50 percent of early-onset familial AD. Mutations are fully penetrant and associated with an earlier median age of onset (43 years) compared with <em>APP</em> and <em>PSEN2</em> mutations  (<a class="graphic graphic_figure graphicRef97086" href="/z/d/graphic/97086.html" rel="external">figure 1</a>) [<a href="#rid14">14</a>]. In longitudinal kindred studies, preclinical cognitive decline is evident more than 10 years before the onset of clinical impairment [<a href="#rid25">25</a>].</p><p>Several different functions have been ascribed to PSEN1, including regulation of intracellular calcium signaling, cell cycle and cell death, trafficking of membrane proteins, regulation of β-catenin stability, and Notch signaling [<a href="#rid26">26</a>]. PSEN1 likely affects AD pathogenesis through its role as a member of the four-protein complex (PSEN1, APH1, PEN2, nicastrin) responsible for γ-secretase cleavage of APP to release Aβ peptides of varying lengths [<a href="#rid26">26</a>].</p><p>Most mutations in <em>PSEN1</em> increase the generation of the highly fibrillogenic Aβ42 species, alter the kinetics of Aβ peptide turnover, and enhance accumulation of Aβ in the brain [<a href="#rid26">26,27</a>]. Blood and cerebrospinal fluid (CSF) levels of Aβ are also elevated. The majority of <em>PSEN1</em> mutations are missense mutations, but small deletions and insertions have been described as well [<a href="#rid28">28</a>].</p><p class="headingAnchor" id="H2663406"><span class="h2">Presenilin 2</span><span class="headingEndMark"> — </span>The <em>PSEN2</em> gene is located on chromosome 1q and encodes the protein product, PSEN2. Fewer than 20 <em>PSEN2 </em>mutations have been described, making it the rarest form of early-onset familial AD. The age of onset in reported cases is later and varies more widely with <em>PSEN2</em> mutations than it does with mutations in <em>APP</em> or <em>PSEN1</em>. Mutations are estimated to be 95 percent penetrant, meaning that up to 5 percent of patients carrying a disease-causing mutation will not develop symptoms of AD in their lifetime [<a href="#rid29">29-32</a>]. This contrasts with <em>APP</em> and <em>PSEN1</em> mutations, which are felt to be fully penetrant.</p><p>The function of PSEN2 and the role of <em>PSEN2 </em>mutations in the pathogenesis of AD are not well understood. <em>PSEN2</em> mutations may act in part by enhancing apoptotic activity that leads to neurodegeneration [<a href="#rid33">33</a>]. Similar to <em>PSEN1</em> mutations, <em>PSEN2</em> mutations alter the cleavage activity of γ-secretase and increase the ratio of Aβ42 to Aβ40. <em>PSEN2</em> is approximately 60 percent homologous to <em>PSEN1</em>, and may represent a very early chromosomal separation or partial duplication from the <em>PSEN1</em> gene.</p><p class="headingAnchor" id="H912645"><span class="h2">Trisomy 21</span><span class="headingEndMark"> — </span>Adults with trisomy 21 (Down syndrome) commonly develop clinical and neuropathologic features of AD by the fifth decade of life due to the presence of an extra copy of the <em>APP</em> gene, the locus for which is on the long arm of chromosome 21. This results in increased production of messenger ribonucleic acid (mRNA) and subsequently APP protein [<a href="#rid34">34</a>].</p><p class="headingAnchor" id="H3679136792"><span class="h2">Others</span><span class="headingEndMark"> — </span><em>APP</em>, <em>PSEN1</em>, and <em>PSEN2</em> mutations account for approximately two-thirds of familial autosomal dominant AD and less than 10 percent of early-onset AD overall. Rare variants at other loci may contribute to early-onset AD risk, including some that overlap with late-onset AD (LOAD; eg, <em>SORL1</em>, <em>TREM2</em>) and others related to the endolysosomal pathway (eg, <em>RUFY1</em>, <em>PSD2</em>, <em>TCIRG1</em>, <em>RIN3</em>) [<a href="#rid35">35</a>].</p><p class="headingAnchor" id="H2663413"><span class="h1">LATE-ONSET ALZHEIMER DISEASE</span><span class="headingEndMark"> — </span>The genetic basis of late-onset Alzheimer disease (LOAD) is more complex, with susceptibility conferred by a variety of more common but less penetrant genetic factors likely interacting with environmental and epigenetic influences. To date, the most firmly established genetic risk factor for late-onset disease is apolipoprotein E (<em>APOE</em>). Many more candidate genes have been identified through genome-wide association studies (GWAS), but their effects on LOAD risk are generally smaller and many have not been validated independently. Some of the more replicated candidate genes are discussed below.</p><p class="headingAnchor" id="H899448"><span class="h2">Apolipoprotein E</span><span class="headingEndMark"> — </span>The <em>APOE</em> gene is located on chromosome 19 and exists in three alleles: epsilon 2, 3, and 4. The <em>APOE</em> epsilon 4 (ε4) allele was first recognized as a risk factor for LOAD in 1993 [<a href="#rid36">36</a>]; since then, multiple studies have confirmed its importance as a risk factor for AD, and possibly vascular dementia as well [<a href="#rid36">36-47</a>]. </p><p class="headingAnchor" id="H1026217"><span class="h3">Epidemiology</span><span class="headingEndMark"> — </span>The frequency of the <em>APOE </em>ε4 risk allele varies across ethnic groups. In one study in New York city, the allele frequency of the ε4 variant was approximately 21 percent in African Americans and was substantially lower in other groups [<a href="#rid48">48</a>]. Among African populations, the reported frequency ranges from 8 percent in Moroccans to as high as 41 percent in Pygmies [<a href="#rid49">49</a>]. Asian populations generally have lower carrier rates, ranging from 7 percent in the Chinese to 24 percent in Malay Aborigines. Its increased frequency in populations where food is, or was in the recent past, scarce suggests that ε4 is a "thrifty" allele that imparts a competitive advantage through energy conservation/utilization [<a href="#rid49">49</a>]. </p><p class="headingAnchor" id="H1026225"><span class="h3">Strength of association</span><span class="headingEndMark"> — </span>Estimates for the increased risk conferred by the ε4 allele vary by population studied and differ based on age and gender. Individuals with two copies of the ε4 allele are at the highest risk. Typical estimates suggest that one ε4 allele confers two- to threefold increased odds of AD whereas two copies (ε4 homozygous) confer 8- to 12-fold increased odds of AD compared with noncarriers [<a href="#rid10">10,45,47</a>].</p><p>Examples of studies demonstrating the association between <em>APOE</em> ε4 genotype and dementia include:</p><p class="bulletIndent1"><span class="glyph">●</span>In the Rotterdam study, a population-based cohort of 7983 people aged 55 or older, carriers of the ε2/ε4 and ε3/ε4 genotypes each had a relative risk of AD and vascular dementia that was approximately double that of ε3/ε3 carriers [<a href="#rid45">45</a>]. Carriers of the ε4/ε4 genotype had a relative risk of dementia approximately eight times that of ε3/ε3 carriers.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In an analysis of 1030 older adults (&gt;70 years) in the Framingham study, <em>APOE</em> ε4 homozygotes had a 30.1 relative risk (95% CI 11-84) for AD compared with noncarriers, while ε3/ε4 heterozygotes had a relative risk of 3.7 (95% CI 1.9-7.5) [<a href="#rid47">47</a>].</p><p></p><p><em>APOE</em> is a susceptibility gene, not a determinative gene. Patients homozygous for the ε4 allele are much more likely but not absolutely destined to develop dementia. In addition, almost 40 percent of patients with AD do not carry <em>APOE</em> ε4 [<a href="#rid47">47</a>]. </p><p>The <em>APOE</em> ε4 allele has been associated with an earlier age of onset in patients with LOAD [<a href="#rid50">50-53</a>]. In a study that included over 9000 individuals with LOAD, each additional copy of the ε4 allele reduced the age of onset by 2.5 years [<a href="#rid53">53</a>]. The mechanisms of action of <em>APOE</em> ε4 are compatible with earlier onset.</p><p>The <em>APOE</em> ε4 allele has also been associated with the severity of AD. Among the associations are earlier and faster cognitive decline [<a href="#rid54">54</a>], increased hippocampal atrophy on magnetic resonance imaging (MRI) [<a href="#rid55">55,56</a>], more psychiatric complications [<a href="#rid42">42,57</a>], more neuritic plaques and neurofibrillary tangles in all neocortical regions at autopsy [<a href="#rid58">58,59</a>], and decreased survival time [<a href="#rid60">60</a>].</p><p>A variety of factors may influence the impact of <em>APOE</em> ε4 on AD risk:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gender</strong> – Although <em>APOE</em> ε4 is a risk factor for AD in both men and women, the effect is greater in women [<a href="#rid10">10,61-65</a>]. Based on a global meta-analysis of more than 57,000 adults, the differential effect in women compared with men appears to be age-dependent and limited to ages 55 to 70 years for the development of mild cognitive impairment (MCI) and ages 65 to 75 years for the development of AD [<a href="#rid65">65</a>]. The mechanisms underlying this gender- and age-dependent vulnerability are not yet understood. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Race</strong> – The strength of the association between <em>APOE</em> ε4 and AD or cognitive decline among African Americans and Africans is less clear. Studies examining this issue have had conflicting results, with some researchers finding results similar to those of White populations and others finding a lower or even no association [<a href="#rid10">10,41,48,66-71</a>]. Possible explanations for these discrepancies include a lower mean age of the African American population in some studies, heterogeneity of African American subgroups at different study sites, and modification of <em>APOE</em> effect by environmental and genetic factors.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vascular risk factors</strong> – Vascular risk factors (smoking, diabetes, hypertension, hypercholesterolemia) may also modify the risk of cognitive decline in individuals with <em>APOE</em> ε4 [<a href="#rid72">72</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Modifier genes</strong> – The risk associated with <em>APOE</em> ε4 may be modified by other genes or environmental factors. As an example, the saitohin (<em>STH</em>) gene lies within an intron of the human tau gene and may have a role in regulating tau isoforms and thus neurofibrillary tangle deposition [<a href="#rid73">73,74</a>]. An <em>STH</em> gene A to G polymorphism appears to be overrepresented in patients with AD. While this may not be an independent risk factor for AD, the <em>STH</em> polymorphism may be associated with an increased risk of AD in the presence of the <em>APOE ε4</em> allele [<a href="#rid74">74</a>]. Polymorphisms in other genes, such as complement component 3b/4b receptor-1 (<em>CR1</em>), appear to lower risk of AD among <em>APOE ε4</em> carriers [<a href="#rid75">75</a>]. </p><p></p><p>In contrast to the ε4 allele, epidemiologic as well as pathologic studies have suggested a protective effect for the ε2 allele in AD [<a href="#rid47">47,58,76</a>].</p><p class="headingAnchor" id="H1026240"><span class="h3">Proposed mechanism</span><span class="headingEndMark"> — </span>The mechanism whereby <em>APOE</em> ε4 influences the development of AD is not known and may involve multiple pathways.</p><p>APOE is a prevalent lipoprotein in brain, involved in cholesterol homeostasis. It mediates neuronal protection and repair and is felt to be the carrier that aids in removal of amyloid-beta (Aβ) via transport to the bloodstream [<a href="#rid77">77</a>]. </p><p>The three APOE isoforms, ε2, ε3, and ε4, differ in amino acid sequence at residues 112 and 158. At these positions, the alleles ε2, ε3, and ε4 contain cysteine/cysteine, cysteine/arginine, and arginine/arginine, respectively [<a href="#rid78">78,79</a>]. The arginine increases the overall charge on the protein. Functional studies have shown that oxidized ε4 binds Aβ much more rapidly than does ε3 and might affect the sequestration of Aβ in plaques [<a href="#rid80">80</a>]. In addition, the ε4 allele is not as efficient at transferring Aβ to the bloodstream and therefore may allow Aβ to build up over time.</p><p>Alternately, or in addition to these effects, APOE isoforms bind differentially to microtubule-associated protein tau (MAPT), the major component of neurofibrillary tangles, indicating that APOE could affect microtubule function and tangle formation in AD patients [<a href="#rid81">81</a>]. In preclinical models, APOE ε4 affects MAPT pathogenesis via microglial-mediated inflammation and neuronal damage and death [<a href="#rid82">82</a>]. APOE isoforms also differentially affect choline acetyltransferase activity in the hippocampus of AD patients [<a href="#rid83">83</a>] and may alter the lipid transport system associated with compensatory sprouting and synaptic remodeling following AD-associated brain injury [<a href="#rid84">84,85</a>]. </p><p><em>APOE</em> ε4 affects plasma lipid levels and is associated with atherosclerotic vascular disease [<a href="#rid86">86</a>]. In a case-control study, high concentrations of plasma lipoprotein(a) increased the risk of developing LOAD in carriers of the ε4 allele, but not in noncarriers [<a href="#rid87">87</a>]. However, in a prospective cohort study, <em>APOE</em> ε4 was a risk factor for AD, independent from cholesterol, lipid, and lipoprotein levels, suggesting that vascular disease is not the primary mechanism by which <em>APOE</em> ε4 influences the development of AD [<a href="#rid88">88</a>].</p><p><em>APOE</em> may also play a role in early brain development. This was suggested by a study that found alterations in brain volumes of infants according to ε4 carrier status, raising the possibility that such changes could increase vulnerability to the pathobiologic cascades of AD [<a href="#rid89">89</a>].</p><p class="headingAnchor" id="H1026606"><span class="h3">Diagnostic utility</span><span class="headingEndMark"> — </span>Genotyping of <em>APOE</em> adds marginally to the predictive value of clinical criteria for AD and may stratify risk of conversion of amnesic MCI to AD, but both false positives and negatives occur [<a href="#rid90">90,91</a>]. It is therefore not recommended except as part of a research protocol.</p><p class="headingAnchor" id="H899456"><span class="h2">Other candidate genes</span><span class="headingEndMark"> — </span>Aside from <em>APOE</em>, more than 29 other genes have been identified through individual candidate gene studies or GWAS and shown to have statistically significant risk effects in later meta-analyses [<a href="#rid92">92-96</a>]. The average allelic summary odds ratios for these candidates are modest, ranging from 1.1 to 1.5, compared with a single <em>APOE</em> ε4 allele, which confers an approximately fourfold increased odds of disease.</p><p>Some representative meta-analyses and their findings apart from <em>APOE</em>-related risk include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Alzheimer GWAS cohorts from across Europe were pooled to include a total of 6010 cases and 8625 controls [<a href="#rid92">92</a>]. Genome-wide significant associations were found with single nucleotide polymorphisms (SNPs) in clusterin (<em>CLU</em>), also known as <em>APOJ</em>, and <em>CR1</em>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a pooled analysis of 16,000 participants recruited through different AD studies in the United States and Europe, genome-wide significant associations were identified with SNPs in <em>CLU</em> and phosphatidylinositol-binding clathrin assembly protein (<em>PICALM</em>) [<a href="#rid93">93</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Combined data from the Cohorts for Heart and Aging Research in Genetic Epidemiology (CHARGE) and several European cohorts also confirmed significant effects of <em>CLU</em>, <em>PICALM</em>, and <em>BIN1</em> variants. In addition, a region containing the genes <em>EXOC3L2</em>, <em>BLOC1S3</em>, and <em>MARK4</em> surpassed the genome-wide significance threshold [<a href="#rid94">94</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The Alzheimer's Disease Genetics Consortium (ADGC), which includes nearly all existing GWAS datasets in the United States totaling 12,000 cases and 11,000 controls, also confirmed the effects of <em>CLU</em>, <em>PICALM</em>, <em>CR1</em>, and <em>BIN1</em> [<a href="#rid97">97</a>]. Genome-wide significant association signals were also seen at <em>EPHA1</em>, in a cluster of genes that includes <em>MS4A4A</em> and <em>MS4A6E</em>, in SNPs near <em>CD33</em> (which is on chromosome 19, 6 Mb from the <em>APOE </em>locus), and near <em>CD2AP</em> on chromosome 14. A companion meta-analysis replicated many of these findings and also identified one novel locus, <em>ABCA7 </em>[<a href="#rid98">98</a>], which has been validated in subsequent studies [<a href="#rid99">99-104</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a combined ADGC and European dataset, over 74,000 AD cases and controls were analyzed [<a href="#rid105">105</a>]. The increased statistic power afforded by this combined sample yielded 11 additional AD risk loci that surpassed the statistic threshold for genome-wide significance, bringing the total number of robustly replicated LOAD risk loci to 19.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Two subsequently published meta-analyses, one combining all the cohorts listed above with additional ones for a total of over 94,000 AD cases [<a href="#rid95">95</a>], and one using a proxy AD measure (parental history of AD) in the United Kingdom Biobank cohort for a total of over 76,000 cases [<a href="#rid96">96</a>], bring the total of independent AD risk loci to 29. </p><p></p><p>Even combined, the predictive value of these genes for LOAD remains quite modest [<a href="#rid93">93</a>]. As an example, the attributable risks for the first three validated AD genes were estimated to be 25.5 percent for <em>APOE</em>, 8.9 percent for <em>CLU</em>, and 3.8 percent for <em>CR1</em> [<a href="#rid92">92</a>]. Although the population-attributable risk for <em>APOE</em>, <em>CLU</em>, <em>PICALM</em>, and <em>CR1</em> combined was later estimated to be as high as 56 percent [<a href="#rid106">106</a>], this estimate was likely inflated and driven primarily by <em>APOE</em>. Using a true population sample, a separate study reported a very modest increase in the predictive value of a model containing age, sex, <em>APOE</em>,<em> PICALM</em>, and <em>CLU</em> over one containing just age, sex, and <em>APOE</em> [<a href="#rid93">93</a>]. </p><p>There are some data to suggest that rare variants in amyloid precursor protein (<em>APP</em>), presenilin 1 (<em>PSEN1</em>), and presenilin 2 (<em>PSEN2</em>) may contribute to disease risk in LOAD [<a href="#rid107">107</a>]. Rare heterozygous variants in the gene that encodes <em>TREM2</em>, a gene known to be associated with a rare autosomal recessive form of dementia, have been associated with increased risk of LOAD [<a href="#rid108">108-112</a>], as have rare variants in phospholipase D3 (<em>PLD3</em>) [<a href="#rid113">113</a>], <em>SORL1</em> [<a href="#rid114">114</a>], and <em>ABI3 </em>[<a href="#rid112">112</a>]. </p><p>Hexanucleotide repeat expansions in the chromosome 9 open reading frame 72 (<em>C9ORF72</em>) gene have been identified in a small number of families with clinical LOAD, although in most cases review of pathology has revealed findings consistent with frontotemporal lobar degeneration (FTLD) or coexistent FTLD and AD pathology [<a href="#rid115">115-117</a>]. <em>C9ORF72</em> repeat expansions are a common cause of sporadic and familial amyotrophic lateral sclerosis (ALS) and frontotemporal dementia. (See  <a class="medical medical_review" href="/z/d/html/5176.html" rel="external">"Familial amyotrophic lateral sclerosis", section on 'C9ORF72 gene'</a> and  <a class="medical medical_review" href="/z/d/html/14138.html" rel="external">"Frontotemporal dementia: Epidemiology, pathology, and pathogenesis", section on 'C9orf72 expansion'</a>.)</p><p>The role of these and other candidate genes in the pathogenesis of AD is an area of active investigation. While these variants are currently not diagnostically useful, they may offer mechanistic insights that will potentially lead to new therapies. (See <a class="local">'Challenges'</a> below.) </p><p class="headingAnchor" id="H900049"><span class="h1">CHALLENGES</span></p><p><strong>Limitations of linkage analyses</strong> — Linkage studies suffer from several important limitations, the sum of which largely explains why this technique has not been more effective in determining the specific genetic bases of late-onset Alzheimer disease (LOAD). First, the small number of markers used results in low resolution to identify linked regions and the responsible genes. These studies are also vulnerable to locus heterogeneity, which occurs when different families have different AD risk genes. Since linkage statistics basically sum the evidence for a disease gene in a given region over all families, the net evidence for linkage in a given region is often weak, despite the presence of a true risk gene. Many early linkage studies also suffered from insufficient sample size.</p><p><strong>Limitations of candidate gene studies</strong> — Of the very large number of AD loci implicated by candidate gene studies, very few have been replicated consistently. Possible explanations include false-positive results, lack of adequate power to detect or replicate an association because of sample size, lack of informative markers within a gene, locus heterogeneity (different genes underlying the same AD phenotype), and clinical heterogeneity (multiple clinical subtypes associated with different sets of susceptibility genes) [<a href="#rid106">106</a>]. Lack of consistency across studies may also be due to intralocus heterogeneity (ie, different risk mutations within the same gene).</p><p><strong>Limitations of genome-wide association studies</strong> — Although many of the limitations inherent to candidate gene studies have been overcome by genome-wide association studies (GWAS), important limitations and challenges do remain. Overall, GWAS have not explained as much of the variance in AD as was originally expected, a challenge that is not unique to AD [<a href="#rid118">118</a>]. There are several hypotheses about why this might be the case across multiple common diseases. (See  <a class="medical medical_review" href="/z/d/html/2902.html" rel="external">"Genetic association and GWAS studies: Principles and applications", section on 'Missing heritability'</a>.)</p><p>In AD, one possibility is that the majority of the heritability has already been explained by the net effect of the thousands of single nucleotide polymorphisms (SNPs) nominally associated with AD, but that these SNPs fail to meet the multiple test-corrected significance threshold. If true, sample sizes of hundreds of thousands or more subjects would be needed to separate the true from the false associations. Considering the very small effects these SNPs are predicted to have on AD risk, the disease-predictive value or therapeutic target potential gained would likely be minimal. Larger sample sizes do not result in larger effect sizes, however, and the small effect sizes associated with the vast majority of SNPs thus far identified may be the most important impediment to clinical relevance [<a href="#rid118">118</a>]. </p><p>As with the candidate gene approach, many individual GWAS findings over the years have not been verified in independent samples. Several factors contribute to this inconsistency, including variable definitions of cases and controls, subject ascertainment, variability of SNP genotyping platforms and microarray chips, and sample size. </p><p><strong>Unexplained risk</strong> — A basic assumption regarding genetic determinants of a complex disease such as LOAD is that common variants in many genes will each lead to a small rise or fall in the risk of disease, and that the overall risk of disease is determined by the combination of multiple variants and environmental exposures. However, genetic studies to date have a mixed track record, and a substantial proportion of LOAD heritability remains unexplained. </p><p>Aside from the limitations of candidate and genome-wide association studies discussed above, one possibility for this is termed the "common disease-rare variant" theory. This theory would posit that multiple, rare, family-specific mutations in common genes and biologic pathways explain the remaining AD heritability. A large proportion of these rare variants are not detectable using the microarray chips used in GWAS. As the cost of next-generation sequencing becomes increasingly affordable, large-scale projects are underway to identify these rare variants and test them for association with AD using gene-based methods.</p><p>More complex statistic models are also being tested and used in an attempt to explain the remaining AD heritability. As with most complex diseases and biologic systems in general, AD pathogenesis involves multiple proteins in multiple inter- and intracellular pathways with multiple levels of regulation and feedback loops. Pathway and gene set enrichment analyses combine multiple lines of evidence, such as SNP association, gene expression, animal models, and literature mining, to identify pathways and networks involved in disease [<a href="#rid119">119,120</a>]. As an example, an analysis of 2344 AD cases and 7076 controls showed significant enrichment of AD-associated SNPs in genes in several pathways [<a href="#rid119">119</a>]. As expected, the "Alzheimer disease" pathway showed the greatest level of enrichment, but several other pathways were significant, including "regulation of autophagy," "natural killer cell mediated cytotoxicity," "antigen processing and presentation," and "RIG-I-like receptor signaling." </p><p><strong>Translation to therapy</strong> — Despite statistic evidence for association, most functional variants in the established AD risk genes have not yet been identified, and the precise roles of their encoded proteins in AD pathogenesis are poorly understood. To date, no therapeutic interventions have been developed to intervene in the genes and pathways identified through GWAS. Functional studies such as mouse knockout models are required to better understand functions in both the context of normal biology and the pathology of AD.</p><p class="headingAnchor" id="H900056"><span class="h1">GENETIC TESTING</span><span class="headingEndMark"> — </span>Individuals with early-onset AD and those with a family history of AD may inquire about genetic testing, which has become more accessible through clinical laboratories. The utility and advisability of testing differs for early-onset versus late-onset disease, and given the evolving nature of the field, formal genetics consultation should be recommended for families who express an interest in testing. </p><p class="headingAnchor" id="H4579949"><span class="h2">Early-onset Alzheimer disease</span><span class="headingEndMark"> — </span>Genetic tests are commercially available for each of the early-onset, autosomal dominant forms of AD. Testing can either be symptomatic (ie, an individual patient diagnosed with early-onset AD and a family history suggesting autosomal dominant inheritance) or predictive (ie, presymptomatic individuals with a known mutation in their family). Because the range of symptom onset varies more widely than initially recognized, mutations in amyloid precursor protein (<em>APP</em>), presenilin 1 (<em>PSEN1</em>), and presenilin 2 (<em>PSEN2</em>) should still be considered in cases of late-onset AD (LOAD) with a consistent dominantly inherited pattern [<a href="#rid14">14</a>]. Prenatal testing is also available when a disease-causing mutation has been identified. An overview of genetic testing and specifics of available genetics tests are available online at <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fgtr%2F&amp;token=wEsKVFvqlKzpT%2BqOtddW%2Fy3%2BLj0shalBW%2BL1ZyL4tryNPgji1PaJ6Kbd%2Fo1hE9A6&amp;TOPIC_ID=16195" target="_blank">GeneTests</a>. Since multiple mutations in <em>PSEN1</em>, <em>PSEN2</em>, and <em>APP</em> can all cause AD, sequencing the entire coding regions of the genes is necessary to comprehensively assess risk; this is not covered by commercial testing. </p><p>Testing for highly penetrant genetic mutations like <em>APP, PSEN1</em>,<em> </em>and <em>PSEN2</em> carries important implications for family members. Genetic counseling of symptomatic patients should be performed in the presence of the individual's legal guardian or a family member to ensure adequate informed consent and an understanding of the purpose of testing, the possible results, and their implications for other family members [<a href="#rid121">121</a>]. Studies have shown that relatively few family members of individuals with early-onset AD choose to be tested. Although those that are usually cope well with the results [<a href="#rid122">122</a>], depression has been reported [<a href="#rid123">123</a>]. It is ultimately up to the relatives of early-onset AD patients whether to undergo genetic testing. Clinicians and genetic counselors have the responsibility to inform them of the option and communicate the implications of having potentially inherited a dominant mutation with almost complete penetrance. (See  <a class="medical medical_review" href="/z/d/html/2901.html" rel="external">"Genetic testing"</a>.)</p><p class="headingAnchor" id="H4579956"><span class="h2">Late-onset Alzheimer disease</span><span class="headingEndMark"> — </span>For LOAD, the predictive value of the LOAD risk variants described above is extremely limited, with the lone exception of apolipoprotein E epsilon 4 (<em>APOE</em> ε4). <em>APOE</em> genotyping in presymptomatic individuals is controversial and has generally been discouraged because of the low sensitivity and specificity of testing, the lack of preventive options, and the apparent variability of risk conferred by <em>APOE</em> across genders and ethnicities [<a href="#rid121">121</a>]. (See <a class="local">'Strength of association'</a> above.)</p><p>When testing is performed, it appears that most individuals do not suffer undue psychologic harm in the short term after results are revealed, but the long-term impact has not been well studied. In a randomized study, 162 adults who had a parent with AD were randomized to having their ε4 status disclosed or not. Subjects who learned they were ε4-positive and were therefore at increased risk for AD showed no more anxiety, depression, or test-related distress than those who did not learn their genotype. Conversely, test-related distress was reduced among those who learned that they were <em>APOE </em>ε4-negative [<a href="#rid124">124</a>]. In a separate study, codisclosure of information about cardiac risk associated with <em>APOE</em> genotype resulted in lower distress among <em>APOE </em>ε4-positive individuals compared with disclosure of only dementia risk [<a href="#rid125">125</a>].</p><p class="headingAnchor" id="H1026643"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Approaches to gene discovery</strong> – Despite decades of research, much of the heritability of Alzheimer disease (AD) remains unexplained. (See <a class="local">'Challenges'</a> above.)</p><p></p><p class="bulletIndent1">There have been three main strategies employed to identify genetic factors that predispose to the development of AD: linkage analysis, candidate gene studies, and genome-wide association studies (GWAS). (See <a class="local">'Approaches to gene discovery'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Early-onset AD</strong> – Early-onset AD accounts for less than 1 percent of cases and typically follows an autosomal dominant inheritance pattern.</p><p></p><p class="bulletIndent1">To date, pathogenic mutations in three genes have been identified as causative of early-onset AD: amyloid precursor protei<em>n (APP</em>), presenilin <em>1 (PSEN1</em>), and presenilin <em>2 (PSEN2</em>). (See <a class="local">'Early-onset Alzheimer disease'</a> above.)</p><p></p><p class="bulletIndent1">Genetic testing is available for the known causative genes in early-onset AD but has not been widely adopted, likely in part because of the current lack of highly effective preventive or therapeutic strategies. (See <a class="local">'Genetic testing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Late-onset AD (LOAD)</strong> – The genetic basis of LOAD is more complex, with susceptibility conferred by a variety of more common but less penetrant genetic factors, likely interacting with environmental and epigenetic influences.</p><p></p><p class="bulletIndent1">To date, the most firmly established genetic risk factor for late-onset disease is apolipoprotein E epsilon <em>4 (APOE </em>ε4). (See <a class="local">'Late-onset Alzheimer disease'</a> above.)</p><p></p><p class="bulletIndent1"><em>APOE</em> genotyping in presymptomatic individuals is generally discouraged but is becoming more accessible through direct-to-consumer testing. (See <a class="local">'Genetic testing'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Levy-Lahad E, Wijsman EM, Nemens E, et al. A familial Alzheimer's disease locus on chromosome 1. Science 1995; 269:970.</a></li><li><a class="nounderline abstract_t">St George-Hyslop P, Haines J, Rogaev E, et al. Genetic evidence for a novel familial Alzheimer's disease locus on chromosome 14. Nat Genet 1992; 2:330.</a></li><li><a class="nounderline abstract_t">Schellenberg GD, Bird TD, Wijsman EM, et al. Genetic linkage evidence for a familial Alzheimer's disease locus on chromosome 14. Science 1992; 258:668.</a></li><li><a class="nounderline abstract_t">Tanzi RE, Gusella JF, Watkins PC, et al. Amyloid beta protein gene: cDNA, mRNA distribution, and genetic linkage near the Alzheimer locus. Science 1987; 235:880.</a></li><li><a class="nounderline abstract_t">Bertram L, McQueen MB, Mullin K, et al. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat Genet 2007; 39:17.</a></li><li><a class="nounderline abstract_t">Goate A, Chartier-Harlin MC, Mullan M, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 1991; 349:704.</a></li><li><a class="nounderline abstract_t">Sherrington R, Rogaev EI, Liang Y, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 1995; 375:754.</a></li><li><a class="nounderline abstract_t">Renbaum P, Levy-Lahad E. Monogenic determinants of familial Alzheimer's disease: presenilin-2 mutations. Cell Mol Life Sci 1998; 54:910.</a></li><li><a class="nounderline abstract_t">Rogaev EI, Sherrington R, Rogaeva EA, et al. Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature 1995; 376:775.</a></li><li><a class="nounderline abstract_t">Farrer LA, Cupples LA, Haines JL, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 1997; 278:1349.</a></li><li><a class="nounderline abstract_t">Campion D, Dumanchin C, Hannequin D, et al. Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum. Am J Hum Genet 1999; 65:664.</a></li><li><a class="nounderline abstract_t">Janssen JC, Beck JA, Campbell TA, et al. Early onset familial Alzheimer's disease: Mutation frequency in 31 families. Neurology 2003; 60:235.</a></li><li><a class="nounderline abstract_t">Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 2001; 81:741.</a></li><li><a class="nounderline abstract_t">Ryman DC, Acosta-Baena N, Aisen PS, et al. Symptom onset in autosomal dominant Alzheimer disease: A systematic review and meta-analysis. Neurology 2014; 83:253.</a></li><li><a class="nounderline abstract_t">Priller C, Bauer T, Mitteregger G, et al. Synapse formation and function is modulated by the amyloid precursor protein. J Neurosci 2006; 26:7212.</a></li><li><a class="nounderline abstract_t">Eckman CB, Mehta ND, Crook R, et al. A new pathogenic mutation in the APP gene (I716V) increases the relative proportion of A beta 42(43). Hum Mol Genet 1997; 6:2087.</a></li><li><a class="nounderline abstract_t">Rostagno A, Holton JL, Lashley T, et al. Cerebral amyloidosis: amyloid subunits, mutants and phenotypes. Cell Mol Life Sci 2010; 67:581.</a></li><li><a class="nounderline abstract_t">Sahlin C, Lord A, Magnusson K, et al. The Arctic Alzheimer mutation favors intracellular amyloid-beta production by making amyloid precursor protein less available to alpha-secretase. J Neurochem 2007; 101:854.</a></li><li><a class="nounderline abstract_t">Tsubuki S, Takaki Y, Saido TC. Dutch, Flemish, Italian, and Arctic mutations of APP and resistance of Abeta to physiologically relevant proteolytic degradation. Lancet 2003; 361:1957.</a></li><li><a class="nounderline abstract_t">Tomiyama T, Nagata T, Shimada H, et al. A new amyloid beta variant favoring oligomerization in Alzheimer's-type dementia. Ann Neurol 2008; 63:377.</a></li><li><a class="nounderline abstract_t">Di Fede G, Catania M, Morbin M, et al. A recessive mutation in the APP gene with dominant-negative effect on amyloidogenesis. Science 2009; 323:1473.</a></li><li><a class="nounderline abstract_t">Rovelet-Lecrux A, Hannequin D, Raux G, et al. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat Genet 2006; 38:24.</a></li><li><a class="nounderline abstract_t">Sleegers K, Brouwers N, Gijselinck I, et al. APP duplication is sufficient to cause early onset Alzheimer's dementia with cerebral amyloid angiopathy. Brain 2006; 129:2977.</a></li><li><a class="nounderline abstract_t">Cabrejo L, Guyant-Maréchal L, Laquerrière A, et al. Phenotype associated with APP duplication in five families. Brain 2006; 129:2966.</a></li><li><a class="nounderline abstract_t">Aguirre-Acevedo DC, Lopera F, Henao E, et al. Cognitive Decline in a Colombian Kindred With Autosomal Dominant Alzheimer Disease: A Retrospective Cohort Study. JAMA Neurol 2016; 73:431.</a></li><li><a class="nounderline abstract_t">Brunkan AL, Goate AM. Presenilin function and gamma-secretase activity. J Neurochem 2005; 93:769.</a></li><li><a class="nounderline abstract_t">Potter R, Patterson BW, Elbert DL, et al. Increased in vivo amyloid-β42 production, exchange, and loss in presenilin mutation carriers. Sci Transl Med 2013; 5:189ra77.</a></li><li><a class="nounderline abstract_t">Bettens K, Sleegers K, Van Broeckhoven C. Current status on Alzheimer disease molecular genetics: from past, to present, to future. Hum Mol Genet 2010; 19:R4.</a></li><li><a class="nounderline abstract_t">Sherrington R, Froelich S, Sorbi S, et al. Alzheimer's disease associated with mutations in presenilin 2 is rare and variably penetrant. Hum Mol Genet 1996; 5:985.</a></li><li><a class="nounderline abstract_t">Finckh U, Alberici A, Antoniazzi M, et al. Variable expression of familial Alzheimer disease associated with presenilin 2 mutation M239I. Neurology 2000; 54:2006.</a></li><li><a class="nounderline abstract_t">Bird TD, Levy-Lahad E, Poorkaj P, et al. Wide range in age of onset for chromosome 1--related familial Alzheimer's disease. Ann Neurol 1996; 40:932.</a></li><li><a class="nounderline abstract_t">Tedde A, Nacmias B, Ciantelli M, et al. Identification of new presenilin gene mutations in early-onset familial Alzheimer disease. Arch Neurol 2003; 60:1541.</a></li><li><a class="nounderline abstract_t">Wolozin B, Iwasaki K, Vito P, et al. Participation of presenilin 2 in apoptosis: enhanced basal activity conferred by an Alzheimer mutation. Science 1996; 274:1710.</a></li><li><a class="nounderline abstract_t">Oyama F, Cairns NJ, Shimada H, et al. Down's syndrome: up-regulation of beta-amyloid protein precursor and tau mRNAs and their defective coordination. J Neurochem 1994; 62:1062.</a></li><li><a class="nounderline abstract_t">Kunkle BW, Vardarajan BN, Naj AC, et al. Early-Onset Alzheimer Disease and Candidate Risk Genes Involved in Endolysosomal Transport. JAMA Neurol 2017; 74:1113.</a></li><li><a class="nounderline abstract_t">Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993; 261:921.</a></li><li><a class="nounderline abstract_t">Henderson AS, Easteal S, Jorm AF, et al. Apolipoprotein E allele epsilon 4, dementia, and cognitive decline in a population sample. Lancet 1995; 346:1387.</a></li><li><a class="nounderline abstract_t">Corder EH, Saunders AM, Risch NJ, et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet 1994; 7:180.</a></li><li><a class="nounderline abstract_t">Polvikoski T, Sulkava R, Haltia M, et al. Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein. N Engl J Med 1995; 333:1242.</a></li><li><a class="nounderline abstract_t">Nicoll JA, Roberts GW, Graham DI. Apolipoprotein E epsilon 4 allele is associated with deposition of amyloid beta-protein following head injury. Nat Med 1995; 1:135.</a></li><li><a class="nounderline abstract_t">Graff-Radford NR, Green RC, Go RC, et al. Association between apolipoprotein E genotype and Alzheimer disease in African American subjects. Arch Neurol 2002; 59:594.</a></li><li><a class="nounderline abstract_t">Chang JB, Wang PN, Chen WT, et al. ApoE epsilon4 allele is associated with incidental hallucinations and delusions in patients with AD. Neurology 2004; 63:1105.</a></li><li><a class="nounderline abstract_t">Chapman J, Wang N, Treves TA, et al. ACE, MTHFR, factor V Leiden, and APOE polymorphisms in patients with vascular and Alzheimer's dementia. Stroke 1998; 29:1401.</a></li><li><a class="nounderline abstract_t">Skoog I, Hesse C, Aevarsson O, et al. A population study of apoE genotype at the age of 85: relation to dementia, cerebrovascular disease, and mortality. J Neurol Neurosurg Psychiatry 1998; 64:37.</a></li><li><a class="nounderline abstract_t">Slooter AJ, Cruts M, Hofman A, et al. The impact of APOE on myocardial infarction, stroke, and dementia: the Rotterdam Study. Neurology 2004; 62:1196.</a></li><li><a class="nounderline abstract_t">Ballard CG, Morris CM, Rao H, et al. APOE epsilon4 and cognitive decline in older stroke patients with early cognitive impairment. Neurology 2004; 63:1399.</a></li><li><a class="nounderline abstract_t">Myers RH, Schaefer EJ, Wilson PW, et al. Apolipoprotein E epsilon4 association with dementia in a population-based study: The Framingham study. Neurology 1996; 46:673.</a></li><li><a class="nounderline abstract_t">Tang MX, Maestre G, Tsai WY, et al. Relative risk of Alzheimer disease and age-at-onset distributions, based on APOE genotypes among elderly African Americans, Caucasians, and Hispanics in New York City. Am J Hum Genet 1996; 58:574.</a></li><li><a class="nounderline abstract_t">Corbo RM, Scacchi R. Apolipoprotein E (APOE) allele distribution in the world. Is APOE*4 a 'thrifty' allele? Ann Hum Genet 1999; 63:301.</a></li><li><a class="nounderline abstract_t">Hsiung GY, Sadovnick AD, Feldman H. Apolipoprotein E epsilon4 genotype as a risk factor for cognitive decline and dementia: data from the Canadian Study of Health and Aging. CMAJ 2004; 171:863.</a></li><li><a class="nounderline abstract_t">Goldstein FC, Ashley AV, Gearing M, et al. Apolipoprotein E and age at onset of Alzheimer's disease in African American patients. Neurology 2001; 57:1923.</a></li><li><a class="nounderline abstract_t">Olarte L, Schupf N, Lee JH, et al. Apolipoprotein E epsilon4 and age at onset of sporadic and familial Alzheimer disease in Caribbean Hispanics. Arch Neurol 2006; 63:1586.</a></li><li><a class="nounderline abstract_t">Naj AC, Jun G, Reitz C, et al. Effects of multiple genetic loci on age at onset in late-onset Alzheimer disease: a genome-wide association study. JAMA Neurol 2014; 71:1394.</a></li><li><a class="nounderline abstract_t">Martins CA, Oulhaj A, de Jager CA, Williams JH. APOE alleles predict the rate of cognitive decline in Alzheimer disease: a nonlinear model. Neurology 2005; 65:1888.</a></li><li><a class="nounderline abstract_t">Mori E, Lee K, Yasuda M, et al. Accelerated hippocampal atrophy in Alzheimer's disease with apolipoprotein E epsilon4 allele. Ann Neurol 2002; 51:209.</a></li><li><a class="nounderline abstract_t">Geroldi C, Laakso MP, DeCarli C, et al. Apolipoprotein E genotype and hippocampal asymmetry in Alzheimer's disease: a volumetric MRI study. J Neurol Neurosurg Psychiatry 2000; 68:93.</a></li><li><a class="nounderline abstract_t">Scarmeas N, Brandt J, Albert M, et al. Association between the APOE genotype and psychopathologic symptoms in Alzheimer's disease. Neurology 2002; 58:1182.</a></li><li><a class="nounderline abstract_t">Tiraboschi P, Hansen LA, Masliah E, et al. Impact of APOE genotype on neuropathologic and neurochemical markers of Alzheimer disease. Neurology 2004; 62:1977.</a></li><li><a class="nounderline abstract_t">Drzezga A, Grimmer T, Henriksen G, et al. Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease. Neurology 2009; 72:1487.</a></li><li><a class="nounderline abstract_t">Dal Forno G, Carson KA, Brookmeyer R, et al. APOE genotype and survival in men and women with Alzheimer's disease. Neurology 2002; 58:1045.</a></li><li><a class="nounderline abstract_t">Molero AE, Pino-Ramírez G, Maestre GE. Modulation by age and gender of risk for Alzheimer's disease and vascular dementia associated with the apolipoprotein E-epsilon4 allele in Latin Americans: findings from the Maracaibo Aging Study. Neurosci Lett 2001; 307:5.</a></li><li><a class="nounderline abstract_t">Bretsky PM, Buckwalter JG, Seeman TE, et al. Evidence for an interaction between apolipoprotein E genotype, gender, and Alzheimer disease. Alzheimer Dis Assoc Disord 1999; 13:216.</a></li><li><a class="nounderline abstract_t">Qiu C, Kivipelto M, Agüero-Torres H, et al. Risk and protective effects of the APOE gene towards Alzheimer's disease in the Kungsholmen project: variation by age and sex. J Neurol Neurosurg Psychiatry 2004; 75:828.</a></li><li><a class="nounderline abstract_t">Altmann A, Tian L, Henderson VW, et al. Sex modifies the APOE-related risk of developing Alzheimer disease. Ann Neurol 2014; 75:563.</a></li><li><a class="nounderline abstract_t">Neu SC, Pa J, Kukull W, et al. Apolipoprotein E Genotype and Sex Risk Factors for Alzheimer Disease: A Meta-analysis. JAMA Neurol 2017; 74:1178.</a></li><li><a class="nounderline abstract_t">Blair CK, Folsom AR, Knopman DS, et al. APOE genotype and cognitive decline in a middle-aged cohort. Neurology 2005; 64:268.</a></li><li><a class="nounderline abstract_t">Evans DA, Bennett DA, Wilson RS, et al. Incidence of Alzheimer disease in a biracial urban community: relation to apolipoprotein E allele status. Arch Neurol 2003; 60:185.</a></li><li><a class="nounderline abstract_t">Sahota A, Yang M, Gao S, et al. Apolipoprotein E-associated risk for Alzheimer's disease in the African-American population is genotype dependent. Ann Neurol 1997; 42:659.</a></li><li><a class="nounderline abstract_t">Shadlen MF. Effects of age and ethnicity on the link between APOE epsilon4 and Alzheimer disease. JAMA 1998; 279:581; author reply 581.</a></li><li><a class="nounderline abstract_t">Murrell JR, Price B, Lane KA, et al. Association of apolipoprotein E genotype and Alzheimer disease in African Americans. Arch Neurol 2006; 63:431.</a></li><li><a class="nounderline abstract_t">Gureje O, Ogunniyi A, Baiyewu O, et al. APOE epsilon4 is not associated with Alzheimer's disease in elderly Nigerians. Ann Neurol 2006; 59:182.</a></li><li><a class="nounderline abstract_t">Caselli RJ, Dueck AC, Locke DE, et al. Cerebrovascular risk factors and preclinical memory decline in healthy APOE ε4 homozygotes. Neurology 2011; 76:1078.</a></li><li><a class="nounderline abstract_t">Conrad C, Vianna C, Freeman M, Davies P. A polymorphic gene nested within an intron of the tau gene: implications for Alzheimer's disease. Proc Natl Acad Sci U S A 2002; 99:7751.</a></li><li><a class="nounderline abstract_t">Seripa D, Matera MG, D'Andrea RP, et al. Alzheimer disease risk associated with APOE4 is modified by STH gene polymorphism. Neurology 2004; 62:1631.</a></li><li><a class="nounderline abstract_t">Thambisetty M, An Y, Nalls M, et al. Effect of complement CR1 on brain amyloid burden during aging and its modification by APOE genotype. Biol Psychiatry 2013; 73:422.</a></li><li><a class="nounderline abstract_t">Serrano-Pozo A, Qian J, Monsell SE, et al. APOEε2 is associated with milder clinical and pathological Alzheimer disease. Ann Neurol 2015; 77:917.</a></li><li><a class="nounderline abstract_t">Horsburgh K, McCarron MO, White F, Nicoll JA. The role of apolipoprotein E in Alzheimer's disease, acute brain injury and cerebrovascular disease: evidence of common mechanisms and utility of animal models. Neurobiol Aging 2000; 21:245.</a></li><li><a class="nounderline abstract_t">Weisgraber KH, Rall SC Jr, Mahley RW. Human E apoprotein heterogeneity. Cysteine-arginine interchanges in the amino acid sequence of the apo-E isoforms. J Biol Chem 1981; 256:9077.</a></li><li><a class="nounderline abstract_t">Rall SC Jr, Weisgraber KH, Innerarity TL, Mahley RW. Structural basis for receptor binding heterogeneity of apolipoprotein E from type III hyperlipoproteinemic subjects. Proc Natl Acad Sci U S A 1982; 79:4696.</a></li><li><a class="nounderline abstract_t">Strittmatter WJ, Saunders AM, Schmechel D, et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A 1993; 90:1977.</a></li><li><a class="nounderline abstract_t">Strittmatter WJ, Roses AD. Apolipoprotein E and Alzheimer disease. Proc Natl Acad Sci U S A 1995; 92:4725.</a></li><li><a class="nounderline abstract_t">Shi Y, Yamada K, Liddelow SA, et al. ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature 2017; 549:523.</a></li><li><a class="nounderline abstract_t">Poirier J, Delisle MC, Quirion R, et al. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proc Natl Acad Sci U S A 1995; 92:12260.</a></li><li><a class="nounderline abstract_t">Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 1988; 240:622.</a></li><li><a class="nounderline abstract_t">Poirier J. Apolipoprotein E in animal models of CNS injury and in Alzheimer's disease. Trends Neurosci 1994; 17:525.</a></li><li><a class="nounderline abstract_t">Mahley RW, Rall SC Jr. Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet 2000; 1:507.</a></li><li><a class="nounderline abstract_t">Mooser V, Helbecque N, Miklossy J, et al. Interactions between apolipoprotein E and apolipoprotein(a) in patients with late-onset Alzheimer disease. Ann Intern Med 2000; 132:533.</a></li><li><a class="nounderline abstract_t">Kivipelto M, Helkala EL, Laakso MP, et al. Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. Ann Intern Med 2002; 137:149.</a></li><li><a class="nounderline abstract_t">Dean DC 3rd, Jerskey BA, Chen K, et al. Brain differences in infants at differential genetic risk for late-onset Alzheimer disease: a cross-sectional imaging study. JAMA Neurol 2014; 71:11.</a></li><li><a class="nounderline abstract_t">Mayeux R, Saunders AM, Shea S, et al. Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. Alzheimer's Disease Centers Consortium on Apolipoprotein E and Alzheimer's Disease. N Engl J Med 1998; 338:506.</a></li><li><a class="nounderline abstract_t">Petersen RC, Smith GE, Ivnik RJ, et al. Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals. JAMA 1995; 273:1274.</a></li><li><a class="nounderline abstract_t">Lambert JC, Heath S, Even G, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet 2009; 41:1094.</a></li><li><a class="nounderline abstract_t">Harold D, Abraham R, Hollingworth P, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet 2009; 41:1088.</a></li><li><a class="nounderline abstract_t">Seshadri S, Fitzpatrick AL, Ikram MA, et al. Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA 2010; 303:1832.</a></li><li><a class="nounderline abstract_t">Kunkle BW, Grenier-Boley B, Sims R, et al. Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. Nat Genet 2019; 51:414.</a></li><li><a class="nounderline abstract_t">Jansen IE, Savage JE, Watanabe K, et al. Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer's disease risk. Nat Genet 2019; 51:404.</a></li><li><a class="nounderline abstract_t">Naj AC, Jun G, Beecham GW, et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet 2011; 43:436.</a></li><li><a class="nounderline abstract_t">Hollingworth P, Harold D, Sims R, et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet 2011; 43:429.</a></li><li><a class="nounderline abstract_t">Reitz C, Jun G, Naj A, et al. Variants in the ATP-binding cassette transporter (ABCA7), apolipoprotein E ϵ4,and the risk of late-onset Alzheimer disease in African Americans. JAMA 2013; 309:1483.</a></li><li><a class="nounderline abstract_t">Chen JA, Wang Q, Davis-Turak J, et al. A multiancestral genome-wide exome array study of Alzheimer disease, frontotemporal dementia, and progressive supranuclear palsy. JAMA Neurol 2015; 72:414.</a></li><li><a class="nounderline abstract_t">Steinberg S, Stefansson H, Jonsson T, et al. Loss-of-function variants in ABCA7 confer risk of Alzheimer's disease. Nat Genet 2015; 47:445.</a></li><li><a class="nounderline abstract_t">Le Guennec K, Nicolas G, Quenez O, et al. ABCA7 rare variants and Alzheimer disease risk. Neurology 2016; 86:2134.</a></li><li><a class="nounderline abstract_t">Cuyvers E, De Roeck A, Van den Bossche T, et al. Mutations in ABCA7 in a Belgian cohort of Alzheimer's disease patients: a targeted resequencing study. Lancet Neurol 2015; 14:814.</a></li><li><a class="nounderline abstract_t">Van den Bossche T, Sleegers K, Cuyvers E, et al. Phenotypic characteristics of Alzheimer patients carrying an ABCA7 mutation. Neurology 2016; 86:2126.</a></li><li><a class="nounderline abstract_t">Lambert JC, Ibrahim-Verbaas CA, Harold D, et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet 2013; 45:1452.</a></li><li><a class="nounderline abstract_t">Ertekin-Taner N. Genetics of Alzheimer disease in the pre- and post-GWAS era. Alzheimers Res Ther 2010; 2:3.</a></li><li><a class="nounderline abstract_t">Cruchaga C, Haller G, Chakraverty S, et al. Rare variants in APP, PSEN1 and PSEN2 increase risk for AD in late-onset Alzheimer's disease families. PLoS One 2012; 7:e31039.</a></li><li><a class="nounderline abstract_t">Guerreiro R, Wojtas A, Bras J, et al. TREM2 variants in Alzheimer's disease. N Engl J Med 2013; 368:117.</a></li><li><a class="nounderline abstract_t">Hooli BV, Parrado AR, Mullin K, et al. The rare TREM2 R47H variant exerts only a modest effect on Alzheimer disease risk. Neurology 2014; 83:1353.</a></li><li><a class="nounderline abstract_t">Jonsson T, Stefansson H, Steinberg S, et al. Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med 2013; 368:107.</a></li><li><a class="nounderline abstract_t">Pottier C, Wallon D, Rousseau S, et al. TREM2 R47H variant as a risk factor for early-onset Alzheimer's disease. J Alzheimers Dis 2013; 35:45.</a></li><li><a class="nounderline abstract_t">Sims R, van der Lee SJ, Naj AC, et al. Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nat Genet 2017; 49:1373.</a></li><li><a class="nounderline abstract_t">Cruchaga C, Karch CM, Jin SC, et al. Rare coding variants in the phospholipase D3 gene confer risk for Alzheimer's disease. Nature 2014; 505:550.</a></li><li><a class="nounderline abstract_t">Vardarajan BN, Zhang Y, Lee JH, et al. Coding mutations in SORL1 and Alzheimer disease. Ann Neurol 2015; 77:215.</a></li><li><a class="nounderline abstract_t">Harms M, Benitez BA, Cairns N, et al. C9orf72 hexanucleotide repeat expansions in clinical Alzheimer disease. JAMA Neurol 2013; 70:736.</a></li><li><a class="nounderline abstract_t">Majounie E, Abramzon Y, Renton AE, et al. Repeat expansion in C9ORF72 in Alzheimer's disease. N Engl J Med 2012; 366:283.</a></li><li><a class="nounderline abstract_t">Murray ME, DeJesus-Hernandez M, Rutherford NJ, et al. Clinical and neuropathologic heterogeneity of c9FTD/ALS associated with hexanucleotide repeat expansion in C9ORF72. Acta Neuropathol 2011; 122:673.</a></li><li><a class="nounderline abstract_t">Klein C, Lohmann K, Ziegler A. The Promise and Limitations of Genome-wide Association Studies. JAMA 2012; :1.</a></li><li><a class="nounderline abstract_t">Lambert JC, Grenier-Boley B, Chouraki V, et al. Implication of the immune system in Alzheimer's disease: evidence from genome-wide pathway analysis. J Alzheimers Dis 2010; 20:1107.</a></li><li><a class="nounderline abstract_t">Hong MG, Alexeyenko A, Lambert JC, et al. Genome-wide pathway analysis implicates intracellular transmembrane protein transport in Alzheimer disease. J Hum Genet 2010; 55:707.</a></li><li><a class="nounderline abstract_t">Goldman JS, Hahn SE, Catania JW, et al. Genetic counseling and testing for Alzheimer disease: joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors. Genet Med 2011; 13:597.</a></li><li><a class="nounderline abstract_t">Steinbart EJ, Smith CO, Poorkaj P, Bird TD. Impact of DNA testing for early-onset familial Alzheimer disease and frontotemporal dementia. Arch Neurol 2001; 58:1828.</a></li><li><a class="nounderline abstract_t">Quaid KA, Murrell JR, Hake AM, Farlow MR. Presymptomatic genetic testing with an APP mutation. J Genet Couns 2000; :327.</a></li><li><a class="nounderline abstract_t">Green RC, Roberts JS, Cupples LA, et al. Disclosure of APOE genotype for risk of Alzheimer's disease. N Engl J Med 2009; 361:245.</a></li><li><a class="nounderline abstract_t">Christensen KD, Roberts JS, Whitehouse PJ, et al. Disclosing Pleiotropic Effects During Genetic Risk Assessment for Alzheimer Disease: A Randomized Trial. Ann Intern Med 2016; 164:155.</a></li></ol></div><div id="topicVersionRevision">Topic 16195 Version 31.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7638621" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : A familial Alzheimer's disease locus on chromosome 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1303289" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Genetic evidence for a novel familial Alzheimer's disease locus on chromosome 14.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1411576" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Genetic linkage evidence for a familial Alzheimer's disease locus on chromosome 14.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2949367" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Amyloid beta protein gene: cDNA, mRNA distribution, and genetic linkage near the Alzheimer locus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17192785" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1671712" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7596406" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9791533" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Monogenic determinants of familial Alzheimer's disease: presenilin-2 mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7651536" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9343467" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10441572" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12552037" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Early onset familial Alzheimer's disease: Mutation frequency in 31 families.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11274343" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Alzheimer's disease: genes, proteins, and therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24928124" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16822978" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Synapse formation and function is modulated by the amyloid precursor protein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9328472" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : A new pathogenic mutation in the APP gene (I716V) increases the relative proportion of A beta 42(43).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19898742" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Cerebral amyloidosis: amyloid subunits, mutants and phenotypes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17448150" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The Arctic Alzheimer mutation favors intracellular amyloid-beta production by making amyloid precursor protein less available to alpha-secretase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12801742" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Dutch, Flemish, Italian, and Arctic mutations of APP and resistance of Abeta to physiologically relevant proteolytic degradation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18300294" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : A new amyloid beta variant favoring oligomerization in Alzheimer's-type dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19286555" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : A recessive mutation in the APP gene with dominant-negative effect on amyloidogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16369530" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16921174" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : APP duplication is sufficient to cause early onset Alzheimer's dementia with cerebral amyloid angiopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16959815" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Phenotype associated with APP duplication in five families.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26902171" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Cognitive Decline in a Colombian Kindred With Autosomal Dominant Alzheimer Disease: A Retrospective Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15857382" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Presenilin function and gamma-secretase activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23761040" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Increased in vivo amyloid-β42 production, exchange, and loss in presenilin mutation carriers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20388643" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Current status on Alzheimer disease molecular genetics: from past, to present, to future.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8817335" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Alzheimer's disease associated with mutations in presenilin 2 is rare and variably penetrant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10822446" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Variable expression of familial Alzheimer disease associated with presenilin 2 mutation M239I.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9007102" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Wide range in age of onset for chromosome 1--related familial Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14623725" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Identification of new presenilin gene mutations in early-onset familial Alzheimer disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8939861" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Participation of presenilin 2 in apoptosis: enhanced basal activity conferred by an Alzheimer mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8113792" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Down's syndrome: up-regulation of beta-amyloid protein precursor and tau mRNAs and their defective coordination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28738127" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Early-Onset Alzheimer Disease and Candidate Risk Genes Involved in Endolysosomal Transport.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8346443" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7475820" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Apolipoprotein E allele epsilon 4, dementia, and cognitive decline in a population sample.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7920638" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7566000" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7585009" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Apolipoprotein E epsilon 4 allele is associated with deposition of amyloid beta-protein following head injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11939894" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Association between apolipoprotein E genotype and Alzheimer disease in African American subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15452311" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : ApoE epsilon4 allele is associated with incidental hallucinations and delusions in patients with AD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9660395" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : ACE, MTHFR, factor V Leiden, and APOE polymorphisms in patients with vascular and Alzheimer's dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9436725" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : A population study of apoE genotype at the age of 85: relation to dementia, cerebrovascular disease, and mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15079025" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : The impact of APOE on myocardial infarction, stroke, and dementia: the Rotterdam Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15505155" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : APOE epsilon4 and cognitive decline in older stroke patients with early cognitive impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8618665" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Apolipoprotein E epsilon4 association with dementia in a population-based study: The Framingham study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8644717" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Relative risk of Alzheimer disease and age-at-onset distributions, based on APOE genotypes among elderly African Americans, Caucasians, and Hispanics in New York City.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10738542" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Apolipoprotein E (APOE) allele distribution in the world. Is APOE*4 a 'thrifty' allele?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15477624" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Apolipoprotein E epsilon4 genotype as a risk factor for cognitive decline and dementia: data from the Canadian Study of Health and Aging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11723294" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Apolipoprotein E and age at onset of Alzheimer's disease in African American patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17101827" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Apolipoprotein E epsilon4 and age at onset of sporadic and familial Alzheimer disease in Caribbean Hispanics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25199842" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Effects of multiple genetic loci on age at onset in late-onset Alzheimer disease: a genome-wide association study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16380608" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : APOE alleles predict the rate of cognitive decline in Alzheimer disease: a nonlinear model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11835377" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Accelerated hippocampal atrophy in Alzheimer's disease with apolipoprotein E epsilon4 allele.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10601411" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Apolipoprotein E genotype and hippocampal asymmetry in Alzheimer's disease: a volumetric MRI study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11971084" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Association between the APOE genotype and psychopathologic symptoms in Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15184600" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Impact of APOE genotype on neuropathologic and neurochemical markers of Alzheimer disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19339712" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11940690" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : APOE genotype and survival in men and women with Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11516561" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Modulation by age and gender of risk for Alzheimer's disease and vascular dementia associated with the apolipoprotein E-epsilon4 allele in Latin Americans: findings from the Maracaibo Aging Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10609670" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Evidence for an interaction between apolipoprotein E genotype, gender, and Alzheimer disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15145993" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Risk and protective effects of the APOE gene towards Alzheimer's disease in the Kungsholmen project: variation by age and sex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24623176" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Sex modifies the APOE-related risk of developing Alzheimer disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28846757" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Apolipoprotein E Genotype and Sex Risk Factors for Alzheimer Disease: A Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15668424" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : APOE genotype and cognitive decline in a middle-aged cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12580702" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Incidence of Alzheimer disease in a biracial urban community: relation to apolipoprotein E allele status.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9382479" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Apolipoprotein E-associated risk for Alzheimer's disease in the African-American population is genotype dependent.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9486747" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Effects of age and ethnicity on the link between APOE epsilon4 and Alzheimer disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16533971" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Association of apolipoprotein E genotype and Alzheimer disease in African Americans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16278853" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : APOE epsilon4 is not associated with Alzheimer's disease in elderly Nigerians.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21325652" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Cerebrovascular risk factors and preclinical memory decline in healthy APOEε4 homozygotes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12032355" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : A polymorphic gene nested within an intron of the tau gene: implications for Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15136700" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Alzheimer disease risk associated with APOE4 is modified by STH gene polymorphism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23022416" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Effect of complement CR1 on brain amyloid burden during aging and its modification by APOE genotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25623662" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : APOEε2 is associated with milder clinical and pathological Alzheimer disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10867209" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : The role of apolipoprotein E in Alzheimer's disease, acute brain injury and cerebrovascular disease: evidence of common mechanisms and utility of animal models.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7263700" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Human E apoprotein heterogeneity. Cysteine-arginine interchanges in the amino acid sequence of the apo-E isoforms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6289314" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Structural basis for receptor binding heterogeneity of apolipoprotein E from type III hyperlipoproteinemic subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8446617" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7761390" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Apolipoprotein E and Alzheimer disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28959956" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8618881" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3283935" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Apolipoprotein E: cholesterol transport protein with expanding role in cell biology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7532337" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Apolipoprotein E in animal models of CNS injury and in Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11701639" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Apolipoprotein E: far more than a lipid transport protein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10744589" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Interactions between apolipoprotein E and apolipoprotein(a) in patients with late-onset Alzheimer disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12160362" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24276092" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Brain differences in infants at differential genetic risk for late-onset Alzheimer disease: a cross-sectional imaging study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9468467" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. Alzheimer's Disease Centers Consortium on Apolipoprotein E and Alzheimer's Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7646655" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19734903" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19734902" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20460622" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Genome-wide analysis of genetic loci associated with Alzheimer disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30820047" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30617256" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer's disease risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21460841" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21460840" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23571587" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Variants in the ATP-binding cassette transporter (ABCA7), apolipoprotein Eϵ4,and the risk of late-onset Alzheimer disease in African Americans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25706306" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : A multiancestral genome-wide exome array study of Alzheimer disease, frontotemporal dementia, and progressive supranuclear palsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25807283" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Loss-of-function variants in ABCA7 confer risk of Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27037229" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : ABCA7 rare variants and Alzheimer disease risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26141617" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Mutations in ABCA7 in a Belgian cohort of Alzheimer's disease patients: a targeted resequencing study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27037232" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Phenotypic characteristics of Alzheimer patients carrying an ABCA7 mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24162737" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20236449" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Genetics of Alzheimer disease in the pre- and post-GWAS era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22312439" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Rare variants in APP, PSEN1 and PSEN2 increase risk for AD in late-onset Alzheimer's disease families.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23150934" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : TREM2 variants in Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25186855" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : The rare TREM2 R47H variant exerts only a modest effect on Alzheimer disease risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23150908" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Variant of TREM2 associated with the risk of Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23380991" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : TREM2 R47H variant as a risk factor for early-onset Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28714976" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24336208" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Rare coding variants in the phospholipase D3 gene confer risk for Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25382023" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Coding mutations in SORL1 and Alzheimer disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23588422" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : C9orf72 hexanucleotide repeat expansions in clinical Alzheimer disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22216764" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Repeat expansion in C9ORF72 in Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22083254" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Clinical and neuropathologic heterogeneity of c9FTD/ALS associated with hexanucleotide repeat expansion in C9ORF72.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : The Promise and Limitations of Genome-wide Association Studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20413860" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Implication of the immune system in Alzheimer's disease: evidence from genome-wide pathway analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20668461" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Genome-wide pathway analysis implicates intracellular transmembrane protein transport in Alzheimer disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21577118" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Genetic counseling and testing for Alzheimer disease: joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11708991" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Impact of DNA testing for early-onset familial Alzheimer disease and frontotemporal dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Presymptomatic genetic testing with an APP mutation</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19605829" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Disclosure of APOE genotype for risk of Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26810768" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Disclosing Pleiotropic Effects During Genetic Risk Assessment for Alzheimer Disease: A Randomized Trial.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
